Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Hydroxyurea vs placebo

Pain alterationa · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

All‐cause mortality · adults and children with sickle cell disease and an increased risk of stroke

Summary of findings ‐ Hydroxyurea and phlebotomy showed no clear difference in death during the study (all deaths) compared with transfusion and chelation (low certainty).

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.42]
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Low

Hydroxyurea vs observation

Pain alteration · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Death during the study · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs placebo

Life‐threatening illness · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 759 participants
Moderate

Hydroxyurea vs observation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs no hydroxyurea

Pain alteration · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs no hydroxyurea

Life‐threatening illness · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs no hydroxyurea

Death during the study · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Hydroxyurea vs no hydroxyurea

Measures of HbF · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low